Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 4/2001

01-06-2001 | Short Communication

Control of irinotecan-induced diarrhea by octreotide after loperamide failure

Authors: Vassilios Barbounis, George Koumakis, Michael Vassilomanolakis, Matina Demiri, Anna P. Efremidis

Published in: Supportive Care in Cancer | Issue 4/2001

Login to get access
Metadata
Title
Control of irinotecan-induced diarrhea by octreotide after loperamide failure
Authors
Vassilios Barbounis
George Koumakis
Michael Vassilomanolakis
Matina Demiri
Anna P. Efremidis
Publication date
01-06-2001
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 4/2001
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s005200000220

Other articles of this Issue 4/2001

Supportive Care in Cancer 4/2001 Go to the issue

Original Article

Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of oral complications

Review Article

Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer

Original article

Influence of glutamine and glycyl-glutamine on in vitro lymphocyte proliferation in children with solid tumors

Original Article

Use of alternative / complementary therapy in breast cancer patients – a psychological perspective

Original Article

Community cancer clinics: patients' perspectives

Original Article

A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of post-chemotherapy neutropenia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits